Jones, Robyn R.
Freeman, Marlene P.
Kornstein, Susan G.
Cooper, Kimberly
Daly, Ella J.
Canuso, Carla M.
Nicholson, Susan
Funding for this research was provided by:
Janssen Research and Development
Article History
Received: 15 December 2020
Accepted: 26 September 2021
First Online: 1 January 2022
Declarations
:
: The TRANSFORM studies were performed in line with the principles of the Declaration of Helsinki. Institutional review boards/ethics committees approved the study protocols and their amendments.
: Written consent was obtained from all patients before they participated in the TRANSFORM studies.
: Not applicable.
: Robyn R. Jones, Kimberly Cooper, Ella Daly, Carla M. Canuso, and Susan Nicholson are employees of Janssen Research & Development, LLC and hold company equity. Dr. Marlene Freeman reports Investigator-Initiated Trials/Research: JayMac, Sage; Advisory Boards: Eliem, Sage; Independent Data Safety and Monitoring Committee: Janssen (Johnson & Johnson), Novartis; Steering Committee for Educational Activities: Medscape; and Educational Activities: WebMD. Dr. Freeman is an employee of Massachusetts General Hospital, and works with the MGH National Pregnancy Registry [Current Registry Sponsors: Teva (2018-present), Alkermes, Inc. (2016-present); Otsuka America Pharmaceutical, Inc. (2008-present); Forest/Actavis (2016-present); Sunovion Pharmaceuticals, Inc. (2011-present)]. As an employee of MGH, Dr. Freeman works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies and NIMH. Dr. Susan Kornstein reports Research Support: Pfizer, Allergan, Marinus, Takeda, Palatin, National Science Foundation; Consulting/Advisory Boards: Pfizer, Marinus, Sage, Acadia, Sunovion, Shire, Allergan, Palatin, AbbVie; and Royalties: Guilford Press.